Business Description
Tourmaline Bio Inc
NAICS : 541714
SIC : 2833
ISIN : US89157D1054
Description
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1271.97 | |||||
| Equity-to-Asset | 0.97 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Future 3-5Y EPS without NRI Growth Rate Estimate | -20.23 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.66 | |||||
| 9-Day RSI | 36.39 | |||||
| 14-Day RSI | 41.85 | |||||
| 3-1 Month Momentum % | 40.55 | |||||
| 6-1 Month Momentum % | -13.95 | |||||
| 12-1 Month Momentum % | 43.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 33.87 | |||||
| Quick Ratio | 33.87 | |||||
| Cash Ratio | 32.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8 | |||||
| Shareholder Yield % | 0.05 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -26 | |||||
| ROA % | -25.44 | |||||
| ROIC % | -211.06 | |||||
| ROC (Joel Greenblatt) % | -3388.85 | |||||
| ROCE % | -30.88 | |||||
| Moat score | 3 | |||||
| Tariff score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.51 | |||||
| Price-to-Tangible-Book | 1.51 | |||||
| EV-to-EBIT | -1.69 | |||||
| EV-to-Forward-EBIT | -4.13 | |||||
| EV-to-EBITDA | -1.69 | |||||
| EV-to-FCF | -1.98 | |||||
| Price-to-Net-Current-Asset-Value | 1.68 | |||||
| Price-to-Net-Cash | 1.74 | |||||
| Earnings Yield (Greenblatt) % | -59.17 | |||||
| FCF Yield % | -19.92 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TRML
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tourmaline Bio Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.21 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 76.03 | ||
| 14-Day RSI | 41.85 | ||
| 14-Day ATR ($) | 1.019972 | ||
| 20-Day SMA ($) | 17.81375 | ||
| 12-1 Month Momentum % | 43.73 | ||
| 52-Week Range ($) | 11.56 - 29.7883 | ||
| Shares Outstanding (Mil) | 25.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tourmaline Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tourmaline Bio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Tourmaline Bio Inc Frequently Asked Questions
What is Tourmaline Bio Inc(TRML)'s stock price today?
The current price of TRML is $16.42. The 52 week high of TRML is $29.79 and 52 week low is $11.56.
When is next earnings date of Tourmaline Bio Inc(TRML)?
The next earnings date of Tourmaline Bio Inc(TRML) is 2025-08-08 Est..
Does Tourmaline Bio Inc(TRML) pay dividends? If so, how much?
Tourmaline Bio Inc(TRML) does not pay dividend.
Guru Commentaries on NAS:TRML
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers